Citius Oncology (CTOR) EBT Margin (2025 - 2026)
Citius Oncology (CTOR) recorded quarterly EBT Margin of 1609.84% in Q1 2026, down 1104.86% quarter-over-quarter from 133.61% in Q4 2025.
Citius Oncology (CTOR) EBT Margin (2025 - 2026) Analysis & Trends
Citius Oncology's EBT Margin history runs 2 years deep, the most recent figure standing at 1609.84% for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 10.97% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 33.51% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 40.73% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 25.87% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 30.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.35% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -156.77% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.70% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 41.45% |
| 10 | Citius Oncology | 71.02 Mn | 68.39 Mn | 1.34 Mn | -1,609.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,609.84% |
| Dec 31, 2025 | -133.61% |